Former users of Janssen Pharmaceuticals’ antipsychotic drug Risperdal continue to feel the impact of a long-undisclosed potential side effect of the medication. The drug is intended to treat schizophrenia and bipolar disorder, however, since its release, multiple misrepresentations about Risperdal have been made to patients and their doctors. In perhaps the most glaring example, some males who have used the drug have developed a disorder called gynecomastia. The condition causes them ...
For Some Risperdal Users, Side Effect Reminder is as Close as Nearest Mirror
Posted February 5, 2017 in Product News and Recalls
J&J to Pay $7.8 Million in Arkansas Risperdal Lawsuit
Posted May 29, 2015 in Product News and Recalls | Verdicts & Settlements
Pharmaceutical giant Johnson & Johnson has agreed to pay $7.8 million to settle a seven-and-a-half-year-old Risperdal lawsuit, the Arkansas Democrat-Gazette reports. The state of Arkansas filed the lawsuit in 2007, alleging that Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, unlawfully marketed its antipsychotic drug Risperdal to Arkansas doctors.
The lawsuit claimed that Johnson & Johnson put patients at risk by not fully disclosing the ...
continue reading...J&J CEO’s Pay Rises 48%
Posted April 3, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
Johnson & Johnson Chairman and Chief Executive Alex Gorsky’s total pay rose 48 percent in 2014, an article from the Wall Street Journal Reports. Board members say they made the decision based on Johnson & Johnson’s success in achieving short- and long-term financial goals and building on the momentum of its pharmaceutical business.
Despite these positive reviews, 2014 was a year fraught with ...
continue reading...Former FDA Commissioner May Testify Against Johnson & Johnson in Risperdal Lawsuit
Posted January 28, 2015 in Product News and Recalls
Ongoing litigation against the pharmaceutical giant Johnson & Johnson (J&J) involves the allegations of improper and deceitful marketing of their antipsychotic drug, Risperdal. A Risperdal lawsuit being heard in the Philadelphia Common Pleas Court may take an interesting turn with the involvement of a former commissioner from the U.S. Food and Drug Administration (FDA). A recent article from Philly.com discusses the possibility that the former FDA commissioner will be called to testify against Johnson & ...
J&J to Pay Over $2.2 Billion in False Marketing Settlement
Posted November 11, 2013 in Drug and Medical Device Lawsuits | Product News and Recalls | Verdicts & Settlements
Johnson & Johnson (J&J) and its subsidiaries have agreed to pay over $2.2 billion in criminal and civil fines arising out of false marketing claims. The company allegedly promoted off-label uses for various drugs, and provided kickbacks to doctors and pharmacists for prescribing those drugs. The drugs at issue in this suit include Risperdal, Invega (forms of antipsychotic medications), and Natrecor (heart ...
